Carisoprodol

Carisoprodol is a carbamate sedative-hypnotic and centrally acting muscle relaxant first approved for medical use in 1959. Developed as an improvement upon meprobamate, it functions as a prodrug that is metabolized into meprobamate in the body. Prescribed for the short-term treatment of musculoskeletal pain, it also possesses anxiolytic and hypnotic properties. Its effects are often compared to barbiturates, and it has been largely supplanted by benzodiazepines due to safety concerns. Its European Union approval was withdrawn in 2008.

Also known as: Soma, Rela, Myolax, Vanadom, Carisoma, Somadril, Isomeprobamate, Isopropyl meprobamate, Carisoprodolum, Carisoprodolo

Classification

Chemical: Medicine
Psychoactive: Depressant
Tag: 1,3-Propanediol dicarbamate
Tag: Anxiolytic
Tag: Carbamate
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Sedative

Effects

Physical Euphoria
Sedation
Muscle Relaxation
Headache
Nausea
Increased Heart Rate
Cognitive Euphoria
Sociability Enhancement
Anxiety Suppression
Amnesia
Confusion
Motor Control Loss
Cognitive Dysphoria
Disinhibition
External Hallucination
Double Vision
Dulled Perception

Routes of Administration

Oral

Dosage

Heavy: 700+ mg
Light: 100 – 350 mg
Common: 350 – 500 mg
Strong: 500 – 700 mg
Threshold: 100 mg

Duration

Onset: 0.25-1 h
Peak: 1.5-2 h
After Effects: 1-12 h
Offset: 2-4 h
Total Duration: 4-6 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu